Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Galie, R. Barst, B. Brundage, H. A. Ghofrani, R. Oudiz, G. Simonneau (Bologna, Italy; New York, Bend, Torrance, United States Of America; Giessen, Germany; Clamart, France). Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease. Eur Respir J 2011; 38: Suppl. 55, 2299

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension Source: Eur Respir J, 50 (2) 1602493; 10.1183/13993003.02493-2016 Year: 2017 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Arterial stiffness in patients with chronic obstructive pulmonary disease combined with arterial hypertension Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020 Pulmonary hypertension and arterial stiffness in patients with systemic scleroderma Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Pulmonary arterial hypertension in connective tissue diseases Source: Eur Respir Mon 2012; 57: 42-57 Year: 2012 Veno-occlussive lesions and inflammation in pulmonary arterial hypertension associated with connective tissue diseases Source: Annual Congress 2007 - Pulmonary hypertension in the clinic Year: 2007 Double combination therapy in patients with pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 6-8 Year: 2010 Pulmonary arterial hypertension in children Source: Eur Respir J 2003; 21: 155-176 Year: 2003 Pulmonary arterial hypertension associated with connective tissue disease: an integrated approach Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience Year: 2008 Pulmonary hypertension in sickle cell disease Source: Annual Congress 2007 - ACCP1 - Pulmonary hypertension in sickle cell disease Year: 2007 Diagnosis of pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 335s Year: 2005 Exercise training in pulmonary arterial hypertension associated with connective tissue diseases Source: Annual Congress 2012 - Limiting factors in exercise Year: 2012 Exercise limitation in idiopathic pulmonary arterial hypertension (IPAH): there‘s more to it than just the pulmonary circulation Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005 Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia Source: International Congress 2017 – PAH and CTEPH Year: 2017 Single arterial occlusion to locate resistance in patients with pulmonary hypertension Source: Eur Respir J 2003; 21: 31-36 Year: 2003 Pulmonary arterial hypertension in scleroderma – manifestation of systemic endothelial dysfunction Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017 Year: 2018